title: Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer.
abstract: OBJECTIVE
  Recurrent triple-negative breast cancer (TNBC) patients have poor prognoses and limited treatment options, especially after progression during prior chemotherapy. The present study aimed to determine the impact of itraconazole with chemotherapy in these patients.
  
  
  METHODS
  Medical records of recurrent TNBC patients receiving itraconazole with chemotherapy between 2008 and 2012 were retrospectively reviewed.
  
  
  RESULTS
  Thirteen patients who progressed during prior chemotherapy (12 with visceral organ metastases) were enrolled. All patients had received docetaxel, carboplatin, and gemcitabine with itraconazole. Additionally, 3 patients with pleural effusion and 2 with inflammatory breast cancer received bevacizumab. No febrile neutropenia, platelet transfusion, or chemotherapy-related death was observed during treatment with itraconazole. The response rate, median progression-free survival, and median overall survival were 62% (95% confidence interval (CI): 35-88%), 10.8 months (95%CI: 7.6-15.3 months), and 20.4 months (95%CI: 13.1-41.4 months), respectively.
  
  
  CONCLUSIONS
  Chemotherapy with itraconazole is promising for heavily pre-treated TNBC patients.
authors: Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan tsuba@hyo-med.ac.jp.
authors: Hiroshi
authors: H
authors: Tsubamoto
authors: Department of Medical Oncology, Kohnan Hospital, Higashinada-ku, Kobe, Japan.
authors: Takashi
authors: T
authors: Sonoda
authors: Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan Department of Obstetrics and Gynecology, Meiwa General Hospital, Nishinomiya, Hyogo, Japan.
authors: Kayo
authors: K
authors: Inoue
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D005260:Female; D006801:Humans; D058922:Inflammatory Breast Neoplasms / Q000188:drug therapy; D017964:Itraconazole / Q000008:administration & dosage; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy*; D000093542:Gemcitabine
chemical_list: D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D017964:Itraconazole; D016190:Carboplatin; D000093542:Gemcitabine
keywords: Itraconazole; metastatic breast cancer; third-line chemotherapy; triple-negative breast cancer